AKT1 and cancer: Indeed, activating KRAS, BRAF and PIK3CA mutations are able to bypass EGFR pharmacological inhibition, thereby resulting in a constitutive activation of the mitogen-activated protein kinase and AKT pathways, known to play a central role in cancer onset and progression [15].